Welcome to our dedicated page for Enanta Pharmaceuticals SEC filings (Ticker: ENTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Enanta Pharmaceuticals, Inc. filings document a clinical-stage biotechnology issuer focused on small-molecule therapies for viral infections and immunological diseases. Its Form 8-K disclosures cover financial results, Regulation FD clinical-data materials, research and development updates, material agreements and capital-structure information for common stock traded under ENTA on the Nasdaq Global Select Market.
Proxy and annual meeting filings record governance matters including director elections, advisory executive compensation votes, auditor ratification and amendments to the 2019 Equity Incentive Plan. Other event disclosures also document patent litigation matters, including proceedings involving U.S. Patent No. 11,358,953 and Pfizer's COVID-19 antiviral Paxlovid.
Enanta Pharmaceuticals reported royalty-based revenue of $17.2 million for the three months ended March 31, 2026, up from $14.9 million a year earlier, driven by higher MAVYRET/MAVIRET sales at AbbVie. Net loss narrowed to $13.1 million from $22.6 million as research and development spending fell to $19.4 million and general and administrative costs declined to $9.6 million.
For the six-month period, revenue reached $35.8 million and net loss was $25.0 million. The company ended the quarter with $227.0 million in cash, cash equivalents and marketable securities and expects this, plus its retained share of HCV royalties, to fund operations into fiscal 2029. Enanta continues to advance wholly owned RSV and immunology programs, including Phase 2 RSV candidate zelicapavir and a new Phase 1 KIT inhibitor, while carrying a royalty sale liability of $128.8 million related to its OMERS transaction.
Enanta Pharmaceuticals Inc — The Vanguard Group filed an amended Schedule 13G reporting 0 shares beneficially owned of Common Stock, representing 0%, following an internal realignment.
The amendment states that on January 12, 2026 The Vanguard Group, Inc. reorganized and certain subsidiaries or business divisions will report beneficial ownership separately in reliance on SEC Release No. 34-39538. The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
Enanta Pharmaceuticals director Terry Vance received a grant of stock options covering 20,000 shares of common stock. The options have an exercise price of 14.1700 per share and expire on March 11, 2036. Following this grant, Vance holds 20,000 options.
The option award vests monthly in substantially equal installments over one year starting on March 11, 2026, with the final monthly installment vesting no later than the nearest Nasdaq Global Select Market trading day before Enanta’s 2027 annual stockholders’ meeting. This is a compensation-related grant, not an open-market share purchase.
Enanta Pharmaceuticals director Lesley Russell received a stock option grant for 20,000 shares of Common Stock. The option has an exercise price of $14.17 per share and expires on March 11, 2036. It vests in substantially equal monthly installments over one year starting on March 11, 2026, with the final installment vesting before the 2027 annual meeting of stockholders.
ENANTA PHARMACEUTICALS director Kristine Peterson reported a grant of stock options for 20,000 shares of common stock. The options have an exercise price of $14.17 per share, were granted on March 11, 2026, and expire on March 11, 2036. They vest in substantially equal monthly installments over one year starting from the grant date, reflecting a compensation-related award rather than an open-market trade.
Enanta Pharmaceuticals director Yujiro S. Hata received a grant of stock options for 20,000 shares of common stock. The options have a $14.17 exercise price, were granted on March 11, 2026, and expire on March 11, 2036.
The options will vest in substantially equal monthly installments over one year starting from the March 11, 2026 grant date, with the final monthly installment vesting no later than the nearest Nasdaq Global Select Market trading day before the 2027 annual stockholders meeting. Following this grant, Hata holds 20,000 stock options directly.
Enanta Pharmaceuticals director Mark G. Foletta received a grant of stock options covering 20,000 shares of common stock. The options have an exercise price of $14.17 per share, were granted at no cost, and expire on March 11, 2036.
The award vests monthly in substantially equal installments over one year, beginning on March 11, 2026, with the final installment vesting no later than the trading day before the 2027 annual stockholder meeting. Following this grant, Foletta holds options for 20,000 shares directly, reflecting routine equity-based director compensation rather than an open-market purchase or sale.
Enanta Pharmaceuticals director Bruce L. A. Carter received a grant of stock options for 20,000 shares of common stock. The options have an exercise price of $14.17 per share and expire on March 11, 2036. They become exercisable monthly in substantially equal installments over one year starting March 11, 2026, with final vesting no later than the trading day before the 2027 annual stockholders meeting. Following this grant, he holds options on 20,000 shares directly.